InMed Pharmaceuticals (INM) EBT (2021 - 2026)

InMed Pharmaceuticals' EBT history runs 6 years deep, the most recent figure standing at -$2.8 million for Q1 2026.

• On a quarterly basis, EBT fell 35.06% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$7.9 million, a 4.81% increase from a year earlier, with the FY2025 full-year figure at -$8.2 million, down 6.44% from the prior year.
• EBT fell to -$2.8 million in Q1 2026 per INM's latest filing, from -$2.0 million in the prior quarter.
• Across five years, EBT topped out at -$336591.0 in Q2 2023 and bottomed at -$7.9 million in Q2 2022.
• The 5-year median for EBT is -$2.0 million (2025), against an average of -$2.4 million.
• Across the five-year window, EBT soared 95.72% in 2023 and tumbled 473.57% in 2024, its largest moves.
• Year by year, EBT stood at -$2.1 million in 2022, then climbed by 29.55% to -$1.5 million in 2023, then sank by 74.2% to -$2.6 million in 2024, then climbed by 21.23% to -$2.0 million in 2025, then tumbled by 37.65% to -$2.8 million in 2026.
• Per Business Quant, the three latest INM EBT figures stand at -$2.8 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.7 million (Q3 2025).